Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs Endeavour Silver Corp (EXK) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs Endeavour Silver Corp — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $299.53 (market cap $39.89B), while Endeavour Silver Corp trades at $7.98 (market cap $2.39B). The key difference: Alnylam Pharmaceuticals, Inc. is far larger — about 16.7× Endeavour Silver Corp's market cap, and Endeavour Silver Corp is trading nearer its 52-week high, Alnylam Pharmaceuticals, Inc. nearer its low. Which is the better fit depends on your goals.
| ALNY | EXK | |
|---|---|---|
Market Cap | $39.89B | $2.39B |
Sector | Health | Basic Materials |
52-Week High | $491.22 | $14.12 |
52-Week Low | $278.09 | $4.96 |
Enterprise Value | $38.15B | $2.40B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $298.76, down 4.49% today, but maintains a bullish technical outlook with strong support at $290. The company reported robust revenue growth to $3.71 billion in 2025, turning profitable with net income of $313.75 million. Analyst consensus is strongly bullish with a $429.50 price target, supported by positive news on drug pipelines and AI partnerships.
Outlook remains positive driven by expanding product portfolio and strategic collaborations, though risks include clinical trial outcomes and high valuation multiples. Earnings beats in recent quarters reinforce growth trajectory, but dependence on key drug Amvuttra and competitive pressures warrant monitoring for sustained shareholder value.
Endeavour Silver (EXK) trades at $8.08, down 1.94% with bearish technical signals despite strong Q2 2026 production results. The company shows improving fundamentals with Q1 2026 earnings beating estimates at $0.21 per share versus $0.10 expected, while revenue trends project growth from $468M in 2025 to $614M in 2026. Analyst sentiment remains overwhelmingly positive with 11 buy ratings out of 14 total recommendations.
EXK presents a recovery opportunity as silver prices strengthen and production expands, though negative net margins and high valuation ratios pose near-term risks. The expiration of silver collars in June 2026 could unlock significant cash flow, providing catalysts for upside potential despite current technical weakness.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About Endeavour Silver Corp
Endeavour Silver is a mid-tier precious metals mining company. It operates silver-gold mines in Mexico and is focused on growing its production and reserves through exploration and the development of new mining projects.
Read more on EXK →
